BeOne Medicines (ONC) reported Q2 adjusted earnings Wednesday of $2.25 per ADS, up from $0.22 a year earlier.
No comparable FactSet estimate was available.
Revenue for the quarter ended June 30 was $1.32 billion, up from $929.2 million a year earlier.
Analysts polled by FactSet expected $1.24 billion.
The company now expects 2025 total revenue of $5.0 billion to $5.3 billion, compared with its prior outlook of $4.9 billion to $5.3 billion. Analysts surveyed by FactSet expect $5.13 billion.
BeOne Medicines shares were up about 4.5% in recent pre-market activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.